Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.

Abstract

Safety, tolerance and immunogenicity of the purified Vi polysaccharide vaccine (Typhim Vi) against typhoid fever was evaluated in primary school children aged 5-15 years. A total of 435 children were vaccinated, each with a single intramuscular injection in the left deltoid muscle. One hundred and ten children were randomly selected for blood samples on day 0 (pre vaccination) and day 30 (post vaccination). Vi antibodies studied by Radio immuno assay (RIA) on 97(88%) paired sera showed a seroconversion rate of 76.2% and seroprotection rate after vaccination was 74.2%, while 6.2% of children already had protective immunity before vaccination. The vaccine was well tolerated. Most commonly reported reactions were mild pain at site of injection (83%), and a few complained of mild swelling (4.6%), induration (1.1%), itching (1.1%) and headaches (1.4%). All reactions were of mild severity and disappeared within 24 to 48 hours.

• Authors: N B Mirza, I A Wamola, B A Estambale, E Mbithi, M Poillet
• Journal: East African medical journal (East Afr Med J) Vol. 72 Issue 3 Pg. 162-4 (Mar 1995) ISSN: 0012-835X [Print] Kenya
• PMID: 7796767 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Bacterial
• Polysaccharides, Bacterial
• Typhoid-Paratyphoid Vaccines
• Vi polysaccharide vaccine, typhoid
• capsular polysaccharide, Salmonella

Topics

• Adolescent
• Antibodies, Bacterial (blood)
• Child
• Child, Preschool
• Female
• Humans
• Injections, Intramuscular
• Kenya
• Male
• Polysaccharides, Bacterial (administration & dosage, adverse effects, immunology)
• Salmonella typhi (immunology)
• Typhoid-Paratyphoid Vaccines (administration & dosage, adverse effects, immunology)